The provided content does not include any specific quantitative models or factors, nor does it detail their construction, evaluation, or backtesting results. The documents primarily focus on market performance, sentiment, fund flows, ETF premiums/discounts, block trades, and institutional activity. These are descriptive analyses and statistics rather than quantitative models or factor-based methodologies.

Core Viewpoint - Chengdu Xuguang Electronics Co., Ltd. held its 2024 annual performance briefing on March 28, 2025, to engage with investors and address their inquiries regarding the company's future plans and performance [1][8]. Performance Briefing Details - The performance briefing was attended by key executives including Chairman Liu Weidong, Independent Director Yang Lijun, General Manager Zhang Chun, and CFO Xiong Shangrong, who interacted with investors [1]. - The briefing was conducted via an online text interaction format on the Shanghai Stock Exchange Roadshow Center [1]. Investor Inquiries and Company Responses - **Dividend Plan**: The company has established a shareholder return plan for the next three years (2025-2027), which will be submitted for approval at the 2024 annual shareholders' meeting [2]. - **Development Plans**: The management is focused on innovation and is actively seeking new profit growth points, emphasizing a strategy driven by "technological leadership, proactive layout, and sustainable strategy" [3]. - **Technical Advantages**: The company has developed a comprehensive technical layout across three major fields: power equipment, military equipment, and electronic materials, with core technologies supporting current and future business development [4]. - **Nuclear Fusion Sector**: The company is one of the few manufacturers engaged in the research and development of equipment for nuclear fusion, having achieved batch supply of high-power electronic tubes for controlled nuclear fusion applications [5][6]. - **Revenue from Nuclear Fusion Products**: The company has generated sales revenue from its high-power electronic tubes used in the controlled nuclear fusion sector [6]. - **Plans in Nuclear Industry**: The company is advancing its position in the nuclear fusion supply chain, aiming to extend its capabilities from key components to equipment manufacturing [5][6]. - **Lithography Machine Involvement**: The company has developed various models of high-power electronic tubes for lithography machines, which have passed customer verification and are being supplied in batches [7][8]. Additional Information - Detailed information regarding the 2024 annual performance briefing can be accessed through the Shanghai Stock Exchange Roadshow Center [8].

Group 1 - The recombinant protein concept sector rose by 2.32%, ranking fifth among concept sectors, with 40 stocks increasing in value [1] - Notable gainers in the sector included Xilong Science, which hit the daily limit, and other companies like Maiwei Biotech, Hotgen Biotech, and Zexin Pharmaceutical, which rose by 11.05%, 8.16%, and 7.91% respectively [1] - The sector experienced a net inflow of 354 million yuan from main funds, with 23 stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top stocks by net inflow included Xilong Science with 282 million yuan, followed by Huabei Pharmaceutical, Borui Pharmaceutical, and Maiwei Biotech with net inflows of 29.71 million yuan, 27.06 million yuan, and 14.97 million yuan respectively [2][3] - Xilong Science led the sector with a net inflow rate of 30.58%, followed by Innotec and Kexing Pharmaceutical with rates of 13.12% and 11.83% respectively [3] - The overall performance of the recombinant protein sector reflects strong investor interest and capital flow, indicating potential growth opportunities within this industry [2][3]